Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2020 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
November 09, 2020 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing...
November 09, 2020 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s...
November 05, 2020 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2020 Results and Update

EDIT-101 for LCA10 ‒ BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease ‒ on track for IND filing by end of 2020 EDIT-201 for solid tumors ‒ preclinical data to be...
October 29, 2020 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
October 01, 2020 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming...
September 11, 2020 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a...
September 04, 2020 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following...
August 24, 2020 08:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has...
August 06, 2020 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2020 Results and Update

Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020 Plan to file IND for EDIT-301...